Table 2.
Radiomic prognostic index (RPI) in relation to clinicopathological patient characteristics in the study cohort (n = 95) and the MRI validation cohort (n = 82).
| Study Cohort (n = 95) | MRI Validation Cohort (n = 82) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patients (n) |
High RPI (n = 36) |
Low RPI (n = 59) |
p-Value * | Patients (n) |
High RPI (n = 15) |
Low RPI (n = 67) |
p-Value * | |
| Age | 0.54 | 0.59 | ||||||
| <67 years | 46 | 16 (44%) | 30 (51%) | 44 | 9 (60%) | 35 (52%) | ||
| ≥67 years | 49 | 20 (56%) | 29 (49%) | 38 | 6 (40%) | 32 (48%) | ||
| FIGO stage | 0.06 | 0.03 | ||||||
| I–II | 82 | 28 (78%) | 54 (91%) | 67 | 9 (64%) | 58 (88%) | ||
| III–IV | 13 | 8 (22%) | 5 (9%) | 13 | 5 (36%) | 8 (12%) | ||
| Histologic type | 0.67 | 0.53 | ||||||
| Endometrioid | 76 | 28 (78%) | 48 (81%) | 65 | 11 (73%) | 54 (81%) | ||
| Non-endometrioid | 19 | 8 (22%) | 11 (19%) | 17 | 4 (27%) | 13 (19%) | ||
| Histologic grade § | 0.16 | 0.89 | ||||||
| Grade 1–2 | 55 | 17 (47%) | 38 (64%) | 54 | 10 (67%) | 44 (66%) | ||
| Grade 3 | 39 | 19 (53%) | 20 (34%) | 27 | 5 (33%) | 22 (33%) | ||
| ND | 1 | 1 (0%) | 1 (2%) | 1 | 0 (0%) | 1 (1%) | ||
| Myometrial invasion | 0.001 | 0.004 | ||||||
| <50% | 52 | 4 (27%) | 48 (72%) | |||||
| ≥50% | 47 | 10 (28%) | 37 (63%) | 28 | 10 (67%) | 18 (27%) | ||
| ND | 48 | 26 (72%) | 22 (37%) | 2 | 1 (6%) | 1 (1%) | ||
| Lymph node metastases | 0.31 | 0.02 | ||||||
| No | 76 | 27 (75%) | 49 (83%) | 56 | 6 (40%) | 50 (75%) | ||
| Yes | 10 | 6 (17%) | 4 (7%) | 9 | 4 (27%) | 5 (7%) | ||
| ND | 9 | 3 (8%) | 6 (10%) | 17 | 5 (33%) | 12 (18%) | ||
* p-values from Pearson’s chi-square; § endometrioid only; FIGO: The International Federation of Gynecology and Obstetrics; ND: not determined.